Abstract Despite the clinical benefit of PARP1/2 inhibitors (PARPi), which are FDA-approved for the treatment of certain BRCA-mutant cancers, many patients achieve incomplete disease control and develop progressive disease. Motivated by this clinical need, we utilized our CRISPR target discovery screening platform to identify novel targets that synergize with PARP inhibitor treatment. By conducting parallel screens in both BRCA-mutant and wildtype cells, we identified DNA polymerase beta (POLB) as a novel target that - when combined with PARPi - selectively kills BRCA-mutant lines while sparing normal cells. POLB knockout and cDNA rescue experiments using both BRCA1 and BRCA2-mutant isogenic cell lines further demonstrated that the catalytic activity of POLB is required for synthetic lethality with PARPi. Most strikingly, POLB knockout combined with sub-therapeutic doses of PARPi, led to profound tumor regression and prevented in vivo tumor regrowth, even after cessation of drug treatment. Mechanistically, POLB knockout is associated with increased single and double strand DNA breaks, accumulation of poly-ADP-ribose polymers, cell cycle arrest and apoptosis. Together, these results suggest that POLB inhibitors in combination with PARPi have the potential to drive deep and durable responses providing a novel therapeutic option for cancer patients with BRCA1/2-mutations. Citation Format: Madhavi Bandi. POLB knockout is synthetic lethal with PARP inhibition leading to complete and durable responses in BRCA-mutant tumor xenografts [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr B002.